MAPT and Alzheimer disease: In this context, the nonassociation between the CSF Aβ1–42 and the LCT and the association between CSF tau and the LCT may suggest that the LCT could serve as a potential clinical indicator for neurodegeneration in patients with AD or those at risk of developing AD.